Neostem, Inc. Appoints International Expert In Endocrinology And Pharmacology As Vice President Of D

< BACK TO HEALTH starstarstarstarstar   Community - Health Press Release
7th July 2009, 12:29am - Views: 318

Community Health NeoStem, Inc. 1 image


NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as Vice President

of Drug Development and Regulatory Affairs

NEW YORK, July 6 /PRNewswire-AsiaNet/ --

    NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease

collection, processing and long-term storage of adult stem cells for future

medical need, announced today it has appointed Alan G. Harris, M.D., Ph.D.,

FACP, FRCP, as the Company's Vice President of Drug Development and

Regulatory Affairs.

    Among his responsibilities in this position will be overseeing NeoStem's

therapeutic development activities and interfacing with the Chairman of the

Scientific Advisory Board to assist in the execution of the Company's

scientific vision. This will include overseeing the Company's regulatory

activities, working to advance NeoStem's intellectual property portfolio and

licensed technologies, assisting in the development of a chronic wound care

program and developing a regulatory pathway for commercializing stem cell

therapy, including assisting in developing very small embryonic like (VSEL)

stem cell therapy in multiple clinical indications. Upon the completion of

the Company's proposed acquisition of a 51% interest in Suzhou Erye

Pharmaceuticals Company, Ltd., which the Company anticipates closing no later

than the fourth quarter of 2009, Dr. Harris is expected to assist in bringing

new drugs to China to enhance Erye's pipeline in an effort to increase

revenues and provide a higher margin business through their already

established 30 province distribution.

    Dr. Harris has over 20 years of experience working in clinical drug

development in multiple therapeutic areas in the pharmaceutical and

biotechnology industries, having conducted and overseen numerous clinical

trials in over 30 countries including China. He was recently Senior VP of R&D

and Chief Medical Officer at NPS Pharmaceuticals in NJ, where he successfully

launched two Phase III registration programs in Gastroenterology and

Endocrinology. Previously he served as Chief Medical Officer at Manhattan

Pharmaceuticals, Inc., after serving as Therapeutic Head of the Worldwide

Medical Endocrine Care group at Pfizer Inc, New York and, earlier, as Vice

President, Global Healthcare Research & Outcomes and Senior Director of

Medical & Scientific Affairs at Schering-Plough Corp., NJ, where he was

involved in the joint venture with Merck in the clinical development of the

novel cholesterol medication, ezetimibe (Zetia). Dr. Harris earned his MD

from the Louis Pasteur Faculty of Medicine, University of Strasbourg, France,

and his Ph.D. in endocrinology from Erasmus University, Rotterdam, The

Netherlands. He was appointed Associate Professor of Medicine at UCLA School

of Medicine and Director of the Division of Clinical Pharmacology in the

Department of Medicine and Medical Director of the Dept of Technology

Development and Transfer and Clinical Trials at Cedars-Sinai Medical Center.

Dr. Harris during his tenure at Sandoz (Novartis) Pharma in Switzerland,

developed octreotide (Sandostatin(R)) for the treatment of hormone producing

tumors of the gut and pituitary. He is currently Adjunct Professor of

Pharmacology at NYU Medical School and Visiting Professor of Medicine in the

Dept of Endocrinology at Liege University Medical School, Belgium and in the

Dept of Clinical Pharmacology at the University Hospital of Lausanne in

Switzerland. Dr. Harris is a Fellow of the American College of Physicians,

the Royal College of Physicians (UK), the Royal Society of Medicine (UK) and

the American College of Clinical Pharmacology. He has served on the editorial

boards of several international peer reviewed medical journals and has

authored 119 peer reviewed scientific papers in the fields of endocrinology,

diabetes mellitus, gastroenterology, oncology, cardiology, allergy,

immunology and respiratory medicine. He served on the NIH Center for

Scientific Review Special Emphasis Panel for Clinical Cardiovascular Sciences

Study Section and is currently a Trustee of the NYU Hospital for Joint


    Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "We are

extremely pleased to have Dr. Harris join our management team at NeoStem. His

extensive achievements in the academic and entrepreneurial worlds of medicine

indicate the range of his talents that will support the multifaceted growth

of our company that we anticipate over the coming years."

    Dr. Harris stated, "I look forward very much to working with Dr. Smith

and her team on the exciting and creative medical and business opportunities

that NeoStem has under way, both in the United States and abroad. This is an

extraordinary young company with great potential for leadership in the

burgeoning field of stem cell therapies, and I'm delighted to play a part in

its development."

    About NeoStem, Inc.

    NeoStem is developing a network of adult stem cell collection centers

that are focused on enabling people to donate and store their own

(autologous) stem cells when they are young and healthy for their personal

use in times of future medical need. The Company has also entered into

research and development through the acquisition of a worldwide exclusive

license to technology to identify and isolate VSELs (very small

embryonic-like stem cells), which have been shown to have several physical

characteristics that are generally found in embryonic stem cells and is

pursuing other technologies to advance its position in the field of stem cell

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995. Forward-looking

statements reflect management's current expectations, as of the date of this

press release, and involve certain risks and uncertainties. The Company's

actual results could differ materially from those anticipated in these

forward-looking statements as a result of various factors. Factors that could

cause future results to materially differ from the recent results or those

projected in forward-looking statements include the "Risk Factors" described

in the Company's Annual Report on Form 10-K for the fiscal year ended

December 31, 2008 and the Company's other periodic filings with the

Securities and Exchange Commission. The Company's further development is

highly dependent on future medical and research developments and market

acceptance, which is outside its control.


        NeoStem, Inc.

        Robin Smith, Chief Executive Officer

        T: 212-584-4180


    SOURCE:  NeoStem, Inc.

    CONTACT: Robin Smith

             Chief Executive Officer of NeoStem, Inc.



Community Health NeoStem, Inc. 2 image


   Chinese - Traditional (

To view this and other AsiaNet releases please visit

news articles logo NEWS ARTICLES
Contact News Articles |Remove this article